NASDAQ
NEUP
Last Price
US $3.57
KEY FIGURES
MKT CAP
$19.3M
EPS
TTM
$-5.26
PEG
TTM
-
P/E
TTM
N/M
P/S
TTM
1.22x
YIELD
0.00%
GROWTH
Revenue Y/Y
244.91%
(FY vs FY)
EBITDA Y/Y
Cash Flow (DCF)
Fair Value
Market $3.57
—
Default assumptions
EBITDA Multiple
Fair Value
Market $3.57
1.40%
Default assumptions
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Neuphoria Therapeutics Inc. cash flow to debt ratio of 34.10K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Financial stability - Healthy cash flow growth.
Neuphoria Therapeutics Inc.'s free cash flow has increased -626.05% from $-14.68M last year to $77.23M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Neuphoria Therapeutics Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Neuphoria Therapeutics Inc.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.00 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
Neuphoria Therapeutics Inc. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Neuphoria Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Neuphoria Therapeutics Inc. has insufficient data to evaluate this check.
Financial stability - Short term assets vs short term liabilities.
Neuphoria Therapeutics Inc.'s short-term assets of $22.85M exceed its short-term liabilities of $6.41M
Decreasing performance - ROA.
Neuphoria Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Neuphoria Therapeutics Inc.'s return on equity of -113.35%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Neuphoria Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Neuphoria Therapeutics Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Increasing performance - Free cash flow.
Neuphoria Therapeutics Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Neuphoria Therapeutics Inc. has a free cash flow yield of 400.27%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
Neuphoria Therapeutics Inc.'s yearly earnings has increased -97.61% since last year from $-15.49M to $-369.63K, signaling increasing performance
Increasing performance - Healthy revenue growth.
Neuphoria Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Decreasing performance - ROIC.
ROIC -71.97% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Neuphoria Therapeutics Inc.'s 3-year revenue CAGR of 244.38% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Neuphoria Therapeutics Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Neuphoria Therapeutics Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Neuphoria Therapeutics Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Neuphoria Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - EBITDA valuation.
Neuphoria Therapeutics Inc. is undervalued relative to its fair value price of 3.62 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Neuphoria Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Neuphoria Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Neuphoria Therapeutics Inc. has a price-to-book ratio of 0.66x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Neuphoria Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-113.35%
Return on equity
ROIC: -71.97%
Valuation History
-0.32X
Price to Earnings
EV/EBITDA: 0.01X
Cash flow
Profit margin
58.75%
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
EARNINGS FV (GRAHAM)
Fair Value
Market $3.57
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.